148 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
ARRY Array BioPharma Inc. $13.73 $2.91B N/A
Article Searches
Will Tinder Gold Drive Match Group's (MTCH) Q1 Earnings? http://www.zacks.com/stock/news/302408/will-tinder-gold-drive-match-groups-mtch-q1-earnings?cid=CS-ZC-FT-302408 May 04, 2018 - Match Group's (MTCH) first-quarter 2018 earnings to benefit from steady market traction of apps like Tinder, which are driving higher subscriber growth.
What's in the Cards for Inovio (INO) This Earnings Season? http://www.zacks.com/stock/news/302456/whats-in-the-cards-for-inovio-ino-this-earnings-season?cid=CS-ZC-FT-302456 May 04, 2018 - Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.
What's in Store for Penumbra (PEN) This Earnings Season? http://www.zacks.com/stock/news/302451/whats-in-store-for-penumbra-pen-this-earnings-season?cid=CS-ZC-FT-302451 May 04, 2018 - Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.
Envision Healthcare (EVHC) to Report Q1 Earnings: What's Up? http://www.zacks.com/stock/news/302287/envision-healthcare-evhc-to-report-q1-earnings-whats-up?cid=CS-ZC-FT-302287 May 04, 2018 - Envision Healthcare's (EVHC) Q1 earnings should see an upside from higher revenues at both its segments.
What's in Store for Celldex (CLDX) This Earnings Season? http://www.zacks.com/stock/news/302186/whats-in-store-for-celldex-cldx-this-earnings-season?cid=CS-ZC-FT-302186 May 03, 2018 - With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.
What's in the Cards for Geron (GERN) This Earnings Season? http://www.zacks.com/stock/news/302174/whats-in-the-cards-for-geron-gern-this-earnings-season?cid=CS-ZC-FT-302174 May 03, 2018 - With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.
Lucky Seven: An Introduction To My Top Biotechnology Picks https://seekingalpha.com/article/4169005-lucky-seven-introduction-top-biotechnology-picks?source=feed_all_articles May 03, 2018 - We will initiate coverage on seven biotechnology stocks.These seven companies are primarily picked for their current valuation, pipeline prospects, financial figures, and likelihood of near-term share
What's in the Cards for Merrimack (MACK) in Q1 Earnings? http://www.zacks.com/stock/news/302167/whats-in-the-cards-for-merrimack-mack-in-q1-earnings?cid=CS-ZC-FT-302167 May 03, 2018 - Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.
Arris trims losses though revenue falls short in Q1 https://seekingalpha.com/news/3351163-arris-trims-losses-though-revenue-falls-short-q1?source=feed_news_all May 01, 2018 - Arris Group (NASDAQ:ARRS) turned in a mixed report in Q1 earnings, substantially trimming its net loss but seeing revenues fall short of expectations. Net loss on a GAAP basis was $0.07/share, vs. a
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond https://seekingalpha.com/article/4167853-jfs-core-biotech-buys-13-continued-market-headwinds-respond?source=feed_all_articles May 01, 2018 - The thesis for position #18, Ionis Pharmaceuticals, has been added.Weakness in the overall market and biotech sector continues to frustrate (and scare) many investors.I remind readers that I am not a

Pages: 12345678...15

<<<Page 3>